Test name | Cancer Antigen 125 |
---|---|
Other names | CA 125 |
Description | CA 125 is expressed by >80 percent of non-mucinous ovarian epithelial neoplasms. Approximately half of women with metastatic ovarian cancer have an elevated CA 125 level. |
Purpose | Recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum |
Methodology | MEIA, ICMA |
Cancers | Ovarian |
Other cancers | Lung, colorectal, pancreas, primary peritoneal carcinoma |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, Specialty Laboratories, UpToDate™ Web sites |
Exploratory Medline search (8/02/05) |
|
Test name | Cancer Antigen 15-3 |
---|---|
Other names | CA 15-3 |
Description | Elevated serum CA 15-3 concentrations are found in 5 percent of stage I, 29 percent of stage II, 32 percent of stage III and 95 percent of stage IV carcinoma of the breast. Most (96 percent) patients with a CA 15-3 increase of greater than 25 percent have disease progression. Most (nearly 100 percent) patients with a CA 15-3 decrease of greater than 50 percent are responding to treatment. |
Purpose | Recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum |
Methodology | ICMA |
Cancers | Breast |
Clinical use(s) a) Routine: |
|
Source of information | Specialty Laboratories, LabCorps, UpToDate™ Web sites |
Exploratory Medline search (8/02/05) |
|
Test name | Cancer Antigen 19-9 |
---|---|
Other names | CA 19-9 |
Description | CA 19-9 is a mucin-glycoprotein first identified from a human colorectal carcinoma cell line and is present in epithelial tissue of the stomach, gall bladder, pancreas and prostate. Concentrations are increased in patients with pancreatic, gastric, and colon cancer as well as in some nonmalignant conditions. Increasing levels generally indicate disease progression, whereas decreasing levels suggest therapeutic response. |
Purpose | Recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum or plasma |
Methodology | EIA |
Cancers | Colorectal, pancreatic, liver |
Other cancers | Gastric |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorps, and UpToDate™ Web sites. |
Exploratory Medline search (8/02/05) |
|
Test name | Cancer Antigen 27.29 |
---|---|
Other names | CA 27.29 |
Description | Elevated CA 27.29 levels are primarily associated with metastatic breast cancer, where it can be used to monitor the course of disease, response to treatment, and detect disease recurrence. Elevated serum CA 27.29 concentrations are found in 95 percent of stage IV breast cancer. In addition, CA 27.29 has been found to be elevated in lung (43 percent), pancreas (47 percent), ovarian (56 percent), and liver (55 percent) cancer. |
Purpose | Recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum protein |
Methodology | ICMA |
Cancers | Breast |
Other cancers | May also be elevated in lung, pancreas, ovarian, and liver cancer. |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorp, Specialty Labs Web sites |
Exploratory Medline search (5/12/05) |
|
Test name | Carcinoembryonic Antigen |
---|---|
Other names | CEA |
Description | CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. It is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Blood levels are often elevated in patients with disseminated cancers and in some patients with nonmalignant disease. |
Purpose | Secondary prevention, prognostic, recurrence, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Serum |
Methodology | ICMA |
Cancers | Breast, lung, colorectal, pancreas, ovarian |
Clinical use(s) a) Routine: |
|
Clinical use(s) b) Investigational |
|
Source of information | Quest Diagnostics, LabCorps, and UpToDate™ Web sites |
Exploratory Medline search (8/02/05) |
|
Test name | Cathepsin D |
---|---|
Description | This enzyme plays a critical role in protein catabolism and tissue remodeling. Over-expression is associated with non-ductal carcinoma and metastasis at the time of breast cancer diagnosis. |
Purpose | Prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Tissue (formalin-fixed, paraffin-embedded) |
Methodology | IHC |
Cancers | Breast |
Clinical use(s) b) Investigational |
|
Source of information | Quest Diagnostics, LabCorps, and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CBFB/MYH11 fusion protein |
---|---|
Other names | inv(16), t(16;16) |
Description | This inversion results in fusion of the core binding factor ß (CBFß) gene on 16q22 with the smooth muscle myosin heavy chain gene (MYH11) on 16p13. This fusion protein accounts for 16 percent of the chromosomal aberrations associated with AML and patients with inv(16) or t(16;16) generally have relatively good response and long-term disease-free survival rates. |
Purpose | Diagnostic, prognostic, monitoring |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, marrow |
Methodology | PCR |
Cancers | Acute myleomonocytic leukemia (AML subtype M4E0) |
Clinical use(s) b) Investigational |
|
Source of information | Quest Diagnostic and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CD 117, c-kit |
---|---|
Other names | Imatinib mesylate (Gleevec) sensitivity |
Description | The glycoprotein c-kit (CD117) is a member of the receptor tyrosine kinase subclass III family and has been implicated in a number of malignancies. Imatinib mesylate, a tyrosine kinase inhibitor, is effective in treating GISTs and other tumors that express c-kit. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Tissue |
Methodology | IHC |
Cancers | Gastrointestinal stromal tumors, c-kit positive |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CD 20 |
---|---|
Other names | Rituximab (Rituxan) sensitivity |
Description | Rituximab is a genetically engineered, chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B-cell lymphocytes. Since non-Hodgkin's Lymphoma (NHL) subtypes may differ in their response to rituximab, determination of drug sensitivity is important for choosing therapy. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood |
Methodology | Flow cytometry |
Cancers | B-cell non-Hodgkin's lymphoma |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CD 25 (immunohistochemistry and flow cytometry) |
---|---|
Other names | Denileukin diftitox (Ontak) sensitivity |
Description | Denileukin diftitox (Ontak) is a cutaneous T-cell lymphoma (CTCL) therapy that targets the high-affinity interleukin-2 (IL-2) receptor. The IL-2 receptor may exist in a low-affinity form (CD25), an intermediate-affinity form (CD122/CD132), and a high-affinity form (CD25/CD122/CD132). Patients whose malignant cells express the CD25 component of the IL-2 receptor may respond to Ontak therapy. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Tissue (IHC), blood or marrow (flow cytometry) |
Methodology | IHC or flow cytometry |
Cancers | Cutaneous T-cell lymphoma |
Clinical use(s) a) Routine: |
Determine eligibility for denileukin diftitox treatment in patients with persistent or recurrent CTCL |
Source of information | Quest Diagnostics and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CD 33 |
---|---|
Other names | Gemtuzumab (Mylotarg) sensitivity |
Description | Gemtuzumab consists of a recombinant, humanized IgG kappa antibody conjugated to a cytotoxic anti-tumor antibiotic, calicheamicin, which binds specifically to the CD33 antigen. This antigen is found on the surface of leukemic blasts and immature normal cells of myelomonocytic lineage, but not in normal hematopoietic stem cells. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, marrow |
Methodology | Flow cytometry |
Cancers | Acute myeloid leukemia (AML) |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | CD 52 |
---|---|
Other names | Alemtuzumab (Campath) sensitivity |
Description | CD52 is an antigen that can be expressed at high density on the surface of malignant CLL cells. Alemtuzumab is a humanized antibody targeted against CD52 and its binding is necessary for cell death and therapeutic response. |
Purpose | Diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, marrow |
Methodology | Flow cytometry |
Cancers | Chronic lymphocytic leukemia (CLL) |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | Chromosome 18q assay |
---|---|
Other names | 18q/RER, DCC |
Description | Colorectal cancer patients with tumors with chromosome 18 deletion are more likely to have disease recurrence and have a shorter disease-free survival period when compared to patients with two copies of this chromosome. |
Purpose | Diagnostic, prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, tissue |
Methodology | PCR |
Cancers | Colorectal cancer |
Clinical use(s) a) Routine: |
|
Source of information | LabCorps and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | Colaris |
---|---|
Other names | MLH1, MSH2 |
Description | Hereditary nonpolyposis colorectal cancer (HNPCC) accounts for about 3 percent to 5 percent of colorectal cancers (CRCs) and is caused by defects in mismatch repair (MMR) enzymes. These defects may also increase the risk of endometrial, cervical, stomach, ovarian, and other forms of cancer. About 90 percent of individuals with HNPCC have mutations in 1 of 2 MMR genes, MLH1 or MSH2. |
Purpose | Secondary prevention, diagnostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood |
Methodology | PCR |
Cancers | Colorectal |
Other cancers | Endometrial, cervical, stomach, ovarian |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics, LabCorps, UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | Colaris AP |
---|---|
Other names | APC, FAP |
Description | Used to identify patients who may have disease-causing mutations, by sequencing the coding region of the APC gene. Individuals with mutations in this gene are at risk for developing early onset of colon cancer. Identifying these mutations makes allows for presymptomatic diagnosis of familial adenomatous polyposis (FAP). |
Purpose | Secondary prevention, diagnostic |
Availability | LabCorp |
Specimen | Blood |
Methodology | PCR |
Cancers | Colorectal |
Clinical use(s) a) Routine: |
|
Source of information | LabCorp Web site |
Exploratory Medline search (8/2/05) |
|
Test name | Cyclin D1 |
---|---|
Description | D-type cyclins are predominantly expressed in the G1 phase of the cell cycle. The expression pattern of cyclin D1 has been extensively studied in certain cancer types including lymphoma and non-small cell lung cancer. Approximately 30 percent of breast carcinomas are Cyclin D1 positive. Over expression of Cyclin D1 is now a well established criterion for the diagnosis of Mantle Cell Lymphoma, a malignant, non-Hodgkin's lymphoma which is characterized by a unique chromosomal translocation t(11;14). |
Purpose | Diagnostic, prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Blood, tissue |
Methodology | FISH |
Cancers | Mantle cell lymphoma |
Clinical use(s) a) Routine: |
|
Source of information | LabCorp and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|
Test name | E-cadherin |
---|---|
Description | E-cadherin is a calcium-dependent epithelial cell-cell adhesion molecule that is associated with tumor invasiveness and disease progression. Ecadherin under-expression appears to be associated with poor tumor differentiation, progression following radical prostatectomy, and diminished overall survival. |
Purpose | Prognostic |
Availability | Commercial laboratories, academic hospitals |
Specimen | Tissue |
Methodology | IHC |
Cancers | Prostate |
Clinical use(s) a) Routine: |
|
Source of information | Quest Diagnostics and UpToDate™ Web sites |
Exploratory Medline search (8/2/05) |
|